Search Results
Your search for The ASCO Post,The ASCO Post matches 17618 pages
Showing 15651 - 15700p53 Takes Center Stage
BOOKMARKTitle: p53: The Gene That Cracked the Cancer CodeAuthor: Sue ArmstrongPublisher: Bloomsbury PublishingPublication date: November 20, 2014Price: $19.98; hardcover, 288 pages Completed in April 2003, the Human Genome Project was one of the greatest feats of scientific exploration, an inward ...
Nicholas J. Petrelli, MD, Receives Service Award
Nicholas J. Petrelli, MD, Bank of America Endowed Medical Director of the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System, received the 2015 Service Award from the Delaware Bio Science Association. Delaware Bio Science is a trade association focused solely on ...
Cancer Survivors: Facts and Figures
The National Cancer Institute’s Office of Cancer Survivorship recently issued the following data: As of January 2014, it is estimated that there are 14.5 million cancer survivors in the United States. This represents over 4% of the population, according to a report published recently.1 The...
Expect Questions About Physical Activity and Reduced Mortality Risks
A study finding that just doing some leisure time physical activity reduces overall and cancer-specific mortality by 20% and that more activity can provide even greater survival benefits concludes that health-care professionals should encourage inactive patients to perform more leisure time...
Just Engaging in ‘Some’ Leisure Time Physical Activity Reduces Overall and Cancer-Specific Mortality
There’s good news for those who recognize the benefits of exercise but feel they have neither the time nor energy for frequent workouts: A recent study reported in JAMA Internal Medicine1 has found that just performing “some” leisure time physical activity, even below the recommended minimum level, ...
Article on Rare Cancer Generates Enthusiastic Response
The article “Shining a Spotlight on Epithelioid Hemangioendothelioma,” written by Jane Gutkovich and published in the April 10, 2015, issue of The ASCO Post, generated an enthusiastic response from the patient and advocate community of individuals with this rare cancer. Here, we are pleased to...
Andrew Parsa, MD, PhD, Chair of Neurological Surgery at Northwestern, Dies at 48
Andrew Parsa, MD, PhD, the Michael J. Marchese Professor and Chair of the Departments of Neurological Surgery at Feinberg and Northwestern Memorial Hospital, passed away on April 13. He was 48 years old. “We are all shocked and saddened by this great loss. Dr. Parsa was a distinguished scholar, an...
Remembering Multiple Myeloma Patient Advocate Michael S. Katz, MBA
I first met Michael Katz, MBA, in 2004, 3 years after my brother, Dom, was diagnosed with multiple myeloma, and we were at a crossroads in his care and needed advice. Although an experimental regimen of thalidomide (Thalomid) and dexamethasone had successfully put Dom in remission for a year (the...
The Paradox of Positive Thinking
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Unexpectedly Huge Survival Benefit With Pertuzumab and Trastuzumab in HER2-Positive Metastatic Breast Cancer
In my opinion, the combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) is one of the most important advances in the field of metastatic breast cancer in the past 10 years. As recently reported by Swain, my other colleagues, and me and reviewed in this issue of The ASCO Post, the...
Learning to Communicate Science More Effectively
Alan Alda’s passion and appreciation for science extend nearly as far back to his early life as his love of acting. The son of actor Robert Alda, Mr. Alda began his acting career at the age of 16. Although he has appeared in such widely acclaimed films as The Seduction of Joe Tynan, Crimes and...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
A Less Is More View of Medicine
BOOKMARKTitle: Less Medicine, More Health: 7 Assumptions That Drive Too Much Medical CareAuthor: H. Gilbert Welch, MDPublisher: Beacon PressPublication date: March 3, 2015Price: $24.95; hardcover, 241 pages He’s the best physician that knows the worthlessness of most medicines. —Benjamin Franklin...
2015 Oncology Meetings
MAY American Association for Cancer Research: Advances in Brain Cancer ResearchMay 27-30 • Washington, DC For more information: www.aacr.org ASCO Annual MeetingMay 29-June 2 • Chicago, Illinois For more information: am.asco.org 2015 ASCO State Affiliates’ ReceptionMay 31 • Chicago, Illinois For...
The Mechanisms Driving Cancer Pain
For over a decade, Patrick W. Mantyh, PhD, JD, has been investigating the molecular and cellular mechanisms that are involved in cancer-related pain, especially bone pain caused by advanced breast, prostate, and lung cancers. His early laboratory work using mouse models of bone cancer led to an...
Sarcoma of the Arm, Circa 1874
The text and photographs on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photos below are from the volume titled “The Anesthesia Era: 1845–1875.” To view additional photos from this...
ASCO, ACCC Respond to Repeal of Medicare Sustainable Growth Rate Formula
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) responded to the approval of H.R.2, a Medicare-reform bill to end the program’s sustainable growth rate (SGR) formula. ASCO’s Statement ASCO President Peter Paul Yu, MD, FACP, FASCO, praised the ...
Cobas KRAS Mutation Test Receives FDA Approval
Roche announced that the U.S. Food and Drug Administration (FDA) has approved the cobas KRAS Mutation Test for diagnostic use. The real-time polymerase chain reaction (PCR) test is designed to identify KRAS mutations in tumor samples from patients with metastatic colorectal cancer and aid...
FDA Accepts Supplemental Biologics License Application for Nivolumab in Patients With Previously Untreated Advanced Melanoma
The U.S. Food and Drug Administration (FDA) has accepted for filing and review Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for nivolumab (Opdivo) for the treatment of previously untreated patients with unresectable or metastatic melanoma. The FDA also granted Priority...
Clinical Trials Actively Recruiting Patients With Cutaneous Lymphoma
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with newly diagnosed or relapsed or refractory lymphoma of the skin. The studies include observational, phase I, and phase II trials investigating single-agent and...
FDA Grants Fast Track Designation to Evofosfamide for Advanced Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of evofosfamide (TH-302), administered in combination with gemcitabine, for previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer. Evofosfamide is an...
Venetoclax Receives Breakthrough Therapy Designation in Relapsed/Refractory CLL With 17p Deletion
The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to AbbVie’s investigational agent venetoclax (ABT-199) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in patients with 17p deletion. Venetoclax is an investigational oral B-cell...
Mario R. Capecchi, PhD, Recognized With AACR Lifetime Achievement in Cancer Research Award
Mario R. Capecchi, PhD, was honored for his tremendous scientific contributions, which have had a profound impact on the understanding of cancer, with the 12th annual American Association for Cancer Research (AACR) Award for Lifetime Achievement in Cancer Research at the AACR Annual Meeting 2015....
Pembrolizumab vs Ipilimumab: Good vs Better
The treatment landscape for metastatic melanoma has recently undergone a remarkable transformation. Prior to 2011, clinicians and patients were presented with difficult decisions between therapies without proven survival benefit. Now, similarly difficult but much more hopeful choices are posed...
Potential Power of Meaning-Centered Group Psychotherapy in Patients With Advanced Cancer
The recent publication of the results of our National Cancer Institute (NCI) RO1-funded randomized controlled trial of meaning-centered group psychotherapy for advanced cancer patients in the Journal of Clinical Oncology,1 and the accompanying summary published in this issue of The ASCO Post,...
James Allison, PhD, Receives 2015 AACR Pezcoller Award
James Allison, PhD, was named a recipient of the 2015 Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Cancer Research at the 2015 AACR Annual Meeting. Dr. Allison, Chair of Immunology at The University of Texas MD Anderson Cancer Center, was acknowledged ...
Welcome to Multikinase Inhibitors in Radioiodine-Refractory Thyroid Cancer
In the past 2 decades, the incidence of thyroid cancer has risen steeply, with rates now growing by 5.5% annually.1 In 2014, 62,980 new cases of thyroid cancer were diagnosed in the United States. The good news is that, overall, the prognosis of thyroid cancer remains excellent; 97.8% of patients...
A Closer Look at the Disparities in Breast Cancer Outcome by Race and Ethnicity
The report from Dr. Steven Narod and colleagues recently published in JAMA1 and reviewed in this issue of The ASCO Post adds to the growing evidence regarding observed disparities in breast cancer outcomes by race and ethnicity among women in the United States. Since 1990, breast cancer death rates ...
Optimizing Treatment for Small, Lymph Node–Negative, HER2-Overexpressing Breast Cancers
Large, randomized phase III clinical trials showed that the addition of HER2-targeted therapy to chemotherapy for patients with early-stage, HER2-overexpressing breast cancers substantially decreased the risk of recurrence and improved survival. The chemotherapy given in these trials varied, but it ...
Increased Risk of Secondary Bone Marrow Neoplasia After Adjuvant Breast Cancer Treatment: Risk/Benefit Analysis and Biologic Insights
Ever since the early application of adjuvant chemotherapy for breast cancer decades ago, it has been recognized that there is always a price to pay for its success in reducing breast cancer mortality. Most of that “cost” is commonly considered in terms of the potential morbid short- and long-term...
June McKoy Named to NCI Council of Research Advocates
June McKoy, MD, MPH, JD, LLM, MBA, Associate Professor of Medicine and Preventive Medicine at Northwestern University Feinberg School of Medicine and Director of Geriatric Oncology for the Lurie Cancer Center, has been selected by National Cancer Institute (NCI) Director, Douglas Lowy, MD, to join ...
NIH Names Eliseo J. Pérez-Stable, MD, Director of the National Institute on Minority Health and Health Disparities
National Institutes of Health (NIH)Director Francis S. Collins, MD, PhD, has announced the selection of Eliseo J. Pérez-Stable, MD, as Director of the National Institute on Minority Health and Health Disparities (NIMHD). Dr. Pérez-Stable is expected to join NIH in September 2015. “Dr....
Taking the Next Step in a Storied Career
On March 31, 2015, Harold Varmus, MD, left his position as Director of the National Cancer Institute (NCI) to join the faculty of Weill Cornell Medical College in New York as its Lewis Thomas University Professor of Medicine. Dr. Varmus was also named Senior Associate Core Member of the New York...
Exploring the History and Psychology of Pain: Beyond the Clinical Setting
BOOKMARKTitle: The Story of Pain: From Prayer to PainkillersAuthor: Joanna BourkePublisher: Oxford University PressPublication date: 2014Price: $34.95: hardcover, 416 page “Pain may even kill. It may overwhelm the nervous system by its mere magnitude & duration.” —Peter Mere Latham, 1871...
Will the PVS-RIPO Poliovirus Be a Game Changer in the Treatment of Recurrent Glioblastoma?
Although the idea of using viruses to target cancer cells dates back more than 100 years, technologic advances in the genetic engineering of viruses are now making it possible to safely test oncolytic virotherapy as a valid strategy against cancer cells. One type of genetically engineered virus...
MAINSAIL Trial: Worse Outcomes With Addition of Lenalidomide to Docetaxel-Prednisone in Prostate Cancer
The combination of docetaxel plus prednisone has been a standard therapy in advanced prostate cancer since 2004.1 Since then, there have been multiple randomized phase III trials comparing this standard of care with additional drug therapy. None has demonstrated improvement in outcome. Lenalidomide ...
Answers: Case Report on Chronic Myelogenous Leukemia
Question 1: In the current era of tyrosine kinase inhibitor therapy, which prognostic model is best to assess the prognosis of a person with a new diagnosis of CML? Correct Answer: D. All of the above Expert Perspective Despite not being perfect, all of these scores are reasonably effective at...
Prognostic Models in CML
Sokal Score1 Derives from a multivariate analysis of survival of 813 patients diagnosed with chronic phase CML between 1962 and 1981 (0.0116 × (age [years] – 43.4)) + (0.0345 × (spleen size [cm] – 7.51) + (0.188 × ((platelets [109/L]/700)^2 – 0.563)) + (0.0887 × (blasts [%] – 2.10)). Smaller...
Prognostic Models and Front-Line Treatment Options for Chronic-Phase Chronic Myelogenous Leukemia
The ASCO Post is pleased to present “Hematology Expert Review,” an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question, along with expert commentary, can be found in the sidebar. In this installment, we present...
Donald S. Coffey, PhD, Recognized With AACR’s Margaret Foti Award
Donald S. Coffey, PhD, was honored with the 9th Annual American Association for Cancer Research (AACR) Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the AACR Annual Meeting 2015. Dr. Coffey, a fellow of the AACR Academy, and the Catherine Iola and J. Smith...
Stephen Grubbs, MD, to Lead ASCO’s New Clinical Affairs Department
Stephen S. Grubbs, MD, a community oncologist and Managing Partner at Medical Oncology Hematology Consultants, PA, has been named the Senior Director of ASCO’s new Clinical Affairs Department. Dr. Grubbs is a longtime ASCO member and volunteer and the Principal Investigator of the Delaware...
Karen E. Knudsen, PhD, Named Director of Sidney Kimmel Cancer Center at Thomas Jefferson University
Karen E. Knudsen, PhD, has been named the Director of the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University and the Hilary Koprowski Chair of the Department of Cancer Biology of the Sidney Kimmel Medical College of Thomas Jefferson University. Dr. Knudsen has been serving in these...
PARP Inhibitors: The First Potential Treatment of Hereditary Ovarian Cancers
Poly(ADP-ribose) polymerase (PARP) inhibitors are one of the most exciting new classes of agents in development for the treatment of ovarian cancer. Olaparib (Lynparza), the lead oral PARP inhibitor, received accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of...
Managing Breast Cancer in 2015
Since 1990, we have seen an approximate 35% reduction in breast cancer mortality among women in the United States. Three protagonists can share this clinical success story: prevention, early detection, and better therapies. To shed light on the current state of breast cancer research and therapy,...
Richard Pazdur, MD, Receives AACR Public Service Award
Richard Pazdur, MD, was awarded the American Association of Cancer Research’s (AACR) Distinguished Public Service Award at the 2015 AACR Annual Meeting. The Association chose Dr. Pazdur for this award based on his “extraordinary, steadfast leadership in scientific and regulatory affairs” and his...
Pembrolizumab Safe and Effective in Patients With NSCLC, Especially in Those With Tumors Showing High Levels of PD-L1 Expression
Add lung cancer to the growing list of cancers that may derive benefit from immunotherapy. The KEYNOTE-001 trial found that pembrolizumab (Keytruda) achieved durable responses in a proportion of patients with non–small cell lung cancer (NSCLC) and high levels of expression of the protein PD-L1...
Genomic Analyses Point to the Potential of Personalized Care for Liver Cancer Patients
A new study presented at The International Liver Congress™ 2015 in Vienna, Austria, showed that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma, it is possible to identify specific molecular profiles. It is hoped that these ...
Cancer Rates Significantly Increased Among Patients With Hepatitis C
Results presented at The International Liver CongressTM 2015 show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV may be an increased risk of cancer. Study...
NCCN Presents Rodger Winn Award to Daniel G. Coit, MD
At the 20th Annual Conference of the National Comprehensive Cancer Network (NCCN) held in March 2015 in Hollywood, Florida, NCCN presented Daniel G. Coit, MD, with the Rodger Winn Award. The award, named for NCCN’s “founding father” of the Guidelines Program and the first Editor-in-Chief of the...
Expert Point of View: Isaac Brownell, MD, PhD
Isaac Brownell, MD, PhD, Investigator with the Dermatology Branch of the National Cancer Institute, commented on the findings of the Australian ONTRAC trial for The ASCO Post. “This is an interesting finding, and it expands on prior work showing reductions in [ultraviolet]-induced DNA damage and...
